decisionhealth Newsletters, Part B News - 2019 Issue 4 (April)
Find updated coverage terms for genetic sequencing tests; beware restriction risk
Subscribe or sign in to view the full article.
Article Overview
This article is for pathology, molecular diagnostics, billing, and reimbursement professionals who need to track Medicare coverage policy for genomic testing. It summarizes a recent revision to the national coverage determination for next generation sequencing, notes how local contractors may align with the federal policy, and discusses the article’s broader concerns about eligibility, staging, and how coverage interpretation may affect claims processing. The piece also references related CMS and stakeholder guidance that frames the current policy debate.
Why This Topic Matters
Coverage changes for genomic testing can affect whether claims are paid, how laboratories document ordering and eligibility, and how practices coordinate with Medicare administrative contractors. The article helps readers understand the policy landscape so they can monitor coding, documentation, and payer adoption risk.
Article Sections
-
Coverage update for next generation sequencing
Overview of the Medicare policy revision affecting genomic testing and the broader testing context under the national coverage framework.
-
Covered diagnosis codes
Discussion of the diagnosis categories referenced in the updated eligibility list and the related Medicare coverage scope.
-
Watch your early-stage coding
Discussion of the possible impact of the revised coverage language on practices, local payer alignment, and policy interpretation issues.
What You Will Learn
- How the recent Medicare coverage update affects next generation sequencing testing
- Which types of pathology and molecular testing professionals should monitor the policy change
- What broad categories of diagnosis eligibility are implicated by the updated coverage terms
- Why local contractor adoption and policy interpretation may affect claims handling
- What broader documentation and reimbursement concerns the article raises for genomic testing
Who Should Read This
- Pathologists
- Molecular laboratory directors
- Billing staff
- Medical coders
- Reimbursement and compliance staff
- Oncology practices
- Medicare billing professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com